Oxacillin Inj Rx
Generic Name and Formulations:
Oxacillin sodium 1g/vial, 2g/vial, 10g/vial; pwd for IM or IV inj after reconstitution, or IV drip after reconstitution and dilution; sodium content 2.5mEq/g oxacillin sodium.
Various generic manufacturers
Indications for Oxacillin Inj:
Susceptible infections due to penicillinase-producing staphylococci.
Give by IM gluteal inj, or slow IV inj over 10 mins, or IV drip. Mild-to-moderate infections: 250–500mg IM or IV every 4–6 hours. Severe infections: 1g IM or IV every 4–6 hours; treat for at least 14 days, then continue for at least 48 hours after becoming afebrile, asymptomatic, or (–) cultures. Endocarditis or osteomyelitis: may need longer therapy; see literature. Switch to oral therapy as soon as clinically indicated.
Give by IM gluteal inj, or slow IV inj over 10 mins, or IV drip. Premature and neonates: 25mg/kg/day IM or IV. Infants and children <40kg: Mild-to-moderate infections: 50mg/kg/day IM or IV in divided doses every 6 hours; severe infections: 100mg/kg/day IM or IV in divided doses every 4–6 hours; treat for at least 14 days, then continue for at least 48 hours after becoming afebrile, asymptomatic, or (–) cultures. Endocarditis or osteomyelitis: may need longer therapy; see literature. Switch to oral therapy as soon as clinically indicated.
Cephalosporin or other allergy: not recommended. Asthma. Renal impairment: consider dose reduction. Do CBCs, BUN, urinalysis, creatinine levels prior to and weekly during therapy. Monitor renal, hepatic and hematopoietic function in prolonged use. Elderly (esp. IV route). Newborns (monitor). Pregnancy (Cat.B). Nursing mothers.
May be antagonized by tetracycline; avoid. Potentiated by probenecid.
Inj site reactions, rash, serum sickness, GI upset, anaphylaxis, neuropathy, nephropathy, blood dyscrasias, hepatotoxicity.
Formerly known under the brand name Bactocill.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness